Auspex SD-809 Interim Analysis Data Release

Posted July 18, 2014, by LaVonne Goodman, M.D.

A recent press release from Auspex Pharmaceuticals reported on an interim analysis from their ongoing ARC-HD trial that switching from tetrabenazine (Xenazine) to SD-109, resulted in equal control of chorea in Huntington's disease.  SD-109 is a chemically modified form of tetrabenazine that allows for a lower dosing regimen.  It is hoped that lower dosing of SD-109 will result in fewer side effects than the present form tetrabenazine.

PGD for the Prevention of HD

Posted June 10, 2014 by LaVonne Goodman, M.D.

For more than a decade, couples at risk for Huntington's disease have had the option to conceive an unaffected child by utilizing the reproductive process of preimplantation genetic diagnosis (PGD).  If PGD became common practice in HD, it could eliminate the majority of disease for the next generation.  So if PGD has the potential to mostly "wipe out" HD for the next generation, why is it so rarely utilized?

HDBuzz content loading
Treatment Guidelines for Huntington's: Who needs them?

Posted by LaVonne Goodman M.D.

During my years as an internal medicine physician, I have used standard of care guidelines for my patients with conditions like diabetes and heart disease. Guidelines are developed by experts in each disease who translate clinical trial evidence and/or expert experience into recommended care patterns for use in medical offices or at the bedside. When followed, guidelines have been central to improving the quality of care provided by all physicians whether they are specialists or generalists.   


To comment on this article or contact HDDW for any other reason, please email us.

© 2007 HDDW. All Rights Reserved.